A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 76-87

  Mathew, Timothy H ^a   Van Buren, Charles ^b   Kahan, Barry D ^b   Butt, Khalid ^c   Hariharan, Sundaram ^d   Zimmerman, James J ^e  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^e PFIZER INC   (United States)

Author keywords

Efficacy failure; Immunotherapy; Pharmacodynamics; Pharmacokinetics; Sirolimus

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN; STEROID;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HLA MATCHING; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; LIQUID; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUSCLE HYPERTONIA; OPEN STUDY; PNEUMONIA; PREDICTION; PYELONEPHRITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; STEADY STATE; TABLET FORMULATION; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION;

ADMINISTRATION, ORAL; ADULT; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACEUTICAL SOLUTIONS; PREMEDICATION; SIROLIMUS; TABLETS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 29644443431     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005282628     Document Type: Article

References (29)

1. Cecka JM. The UNOS Scientific Renal Transplant Registry: ten years of kidney transplants. Clin Transpl. 1997;1-14.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
3. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Ann Surg. 1991;214:679-688.
4. Pirsch JD, Ploeg RJ, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation. 1996;61:1581-1586.
5. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant. 1994;8:328-331.
6. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
7. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35-43.
8. Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant. 1999;13:209-220.
9. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation. 1999;68:1526-1532.
10. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356:194-202.
11. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. The Rapamune Global Study Group. Transplantation. 2001;71:271-280.
12. Physicians' Desk Reference. 58th ed. Montvale, NJ; Medical Economics Company; 2004.
13. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001;72:777-786.
14. Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 2003;76:364-370.
15. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809-817.
16. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int. 2005;18:22-28.
17. Zimmerman JJ, Harper D, Getsy J, Jusko WJ. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003;43:1168-1176.
18. Taylor PJ, Johnson AG. Quantitative analysis of sirolimus (rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Appl. 1998;718:251-257.
19. Jones K, Saadat-Lajevardi S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther. 2000;22(suppl B):B49-B61.
20. SAS Institute, Inc. SAS User's Guide: Statistics. Cary, NC: SAS Institute, Inc; 1985.
21. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but non-identical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation. 1991;51:486-490.
22. Box GEP, Tidwell PW. Transformation of the independent variables. Technometrics. 1962;4;531-550.
23. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002;2:551-9.
24. Dijoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation. 1992;53:507-513.
25. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int. 1996;50:1110-1117.
26. DiJoseph JF, Mihatsch MJ, Sehgal SN. Renal effects of rapamycin in the spontaneously hypertensive rat. Transpl Int. 1994;7:83-88.
27. Groth CG, Bckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67:1036-1042.
28. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252-1260.
29. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002;2:436-442.